EGFR and neoplasm: Second, the case of a tumor committee that makes the final decision on treatment, which is based on the patient’s clinical and functional status, tumor resectability, number of affected or suspicious lymph nodes and nodal regions, and molecular factors (PDL1, EGFR, ALK, etc.), among other factors, should be discussed.